Apellis Pharmaceuticals, INC 8-K filings

Apellis Pharmaceuticals has been acquired by Biogen Inc. through a merger, with convertible senior notes being modified to reflect the new ownership and terms.

Apellis Pharmaceuticals, Inc. has amended its Executive Separation Benefits and Retention Plan in anticipation of its merger with Biogen Inc., accelerating vesting for certain unvested awards upon termination under specific conditions.

Biogen Inc. will acquire Apellis Pharmaceuticals, Inc. for $41.00 per share in cash plus a contingent value right of up to $4.00 per share, expanding its immunology and rare disease footprint.

Apellis Pharmaceuticals, Inc. announced the election of Mikael Dolsten, M.D., Ph.D., to its Board of Directors as a Class I director, effective March 1, 2026.

Apellis Pharmaceuticals announced preliminary 2025 U.S. net product revenues of $689 million, driven by strong SYFOVRE demand and EMPAVELI's successful launch, positioning the company for profitability.

Apellis Pharmaceuticals, Inc. entered into a Royalty Buy-Down Agreement with Swedish Orphan Biovitrum AB (Publ), receiving an upfront payment of $275 million and reducing Sobi's future royalty obligations by 90%.

Apellis Pharmaceuticals, Inc. announced the successful election of three Class II directors, the ratification of Deloitte & Touche LLP as its independent auditor, and the approval of executive compensation at its Annual Meeting of Stockholders held on June 3, 2025.

Apellis Pharmaceuticals has elected Craig A. Wheeler to its Board of Directors and appointed him to the Audit Committee, effective May 1, 2025.

Apellis Pharmaceuticals announced preliminary 2024 U.S. net product revenues of $709 million, driven by strong sales of SYFOVRE and EMPAVELI, and outlined strategic priorities for continued growth.

Apellis and Sobi's Phase 3 VALIANT study of pegcetacoplan met its primary endpoint, showing a significant reduction in proteinuria for patients with C3G and IC-MPGN.

Apellis Pharmaceuticals held its annual meeting on June 5, 2024, where stockholders elected two Class I directors, ratified the appointment of Deloitte & Touche LLP as the independent auditor, and approved executive compensation.

Apellis Pharmaceuticals has entered into a $475 million senior secured term loan agreement, using a significant portion to buy out its obligations to SFJ Pharmaceuticals.

Apellis Pharmaceuticals announced its fourth quarter and full year 2023 financial results, highlighting significant revenue growth driven by the successful launch of SYFOVRE and continued sales of EMPAVELI.

Apellis Pharmaceuticals has appointed its Chief Commercial Officer, Adam Townsend, as Chief Operating Officer, effective immediately.